Please assess the completion status of the following clinical trial:

Trial Title: VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* low grade B cell lymphoma~* 1 or more sites of disease appropriate for intratumoral injection~* measurable disease other than the injection site~* Performance Status of 1 or better~* Adequate bone marrow, renal and hepatic function~* No active autoimmune disease or systemic immunosuppressive drugs~* Life expectancy \> 4 months~Exclusion Criteria:~* Known HIV~* Known brain metastases~* Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)~* Anticoagulation therapy other than 325mg QD ASA~* Significant cardiovascular disease~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VTX-2337 plus radiation (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).